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Extracellular "signals" in the form of neurotransmitters,
growth factors, hormones, and matrix are known to be key
modulators of cellular phenotype. These agents lead to the
generation of second messenger signals in the plasma mem-
brane and cytosol. In turn, these biochemical events modulate
the expression of a set of so-called immediate-early genes
(lEG), whose induction does not require de novo protein
synthesis. Several years ago, we and others identified several
lEGs [reviewed in 1 and 2]. Of particular interest to our
laboratory has been a subset of lEGs that encode transcription
factors, since as such they might: (I) be the targets for second
messenger events, and (2) activate or repress the transcription
of critical genes required to effect a particular cellular pheno-
type. Thus, immediate-early transcription factors (IETF)
should couple short-term responses in the form of second
messenger events to long-term changes in gene expression
instrumental in altering phenotype.
The current status of the IETFs whose genes have been
cloned is shown in Table 1. c-fos, identified as the cellular
homolog of the v-fos oncogene present in two viruses causing
osteosarcomas, was discovered to be an lEG in serum stimu-
lated fibroblasts in 1984 [3], At that time, it was not known that
fos was a transcription factor that forms heterodimeric com-
plexes with c-jun. c-jun was likewise first identified as the
cellular homolog of the v-jun transforming gene and only
through homology with part of the yeast GCN4 transcription
factor was it suspected to be a transcription factor itself. The
best characterized of the Egr family of IETFs is Egr- 1 (early
growth response gene-I). Egr-1 (also known as Zif 268, Tis 8,
NGFI-A, and Krox 24) (references are in Table 1) was isolated
as a serum inducible lEG in quiescent fibroblasts (G0-G1
transition) utilizing a differential screening protocol [4, 5]. The
gene is induced by mitogen stimulation in every mammalian cell
type tested including B cells, T cells, kidney mesangial, glomer-
ular and tubular epithelial cells, hepatocytes and endothelial
cells. It was also discovered as a nerve growth factor inducible
gene in PC12 pheochromocytoma cells, a physiologic context in
which mitotic cells convert to a non-mitotic state [5, 6] and as a
gene induced by the protein kinase C activator TPA [4, 7]. The
cDNA structure predicts a protein whose carboxy terminus
contains three zinc fingers of the cysteine2-histidine2 type, first
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identified in the Xenopus transcription factor TFIIIA. Table 2
summarizes this work on Egr- 1.
During the last few years, a dozen or so transcription factor
genes have been isolated. Through the generation of chimeric
proteins, it has become clear that transcription factors are
essentially modular in design, with different regions involved in
various functional roles, namely DNA binding, dimerization
and transcriptional activation/repression [8]. The families of
IETFs illustrate these ideas nicely (Table 1). The fos and jun
families all contain basic DNA binding regions and form het-
erodimers via their so-called leucine zipper domains. Similarly,
the Egr family contains highly related proteins in the DNA
binding zinc finger domain but which differ significantly outside
this region [91. This review will focus on the Egr family of
transcription factors. For a more comprehensive account, the
reader is referred to a recent review on this subject [1]. Here,
emphasis is placed on recent data and on providing a perspec-
tive on future directions.
Several studies have started identifying the events—from cell
surface to second messengers—which modulate Egr-l expres-
sion. Identification of the "upstream" or "proximal" events
can be done either in the context of mitogenesis or in other
situations in which Egr-l mRNA levels change (Table 2). The
following comments will be restricted to cell proliferation and to
studies conducted primarily in fibroblasts. Multiple kinases
regulate Egr-1 expression [10]. For example, it has been known
that activation of the PDGF receptor or the EGF receptor by
their cognate ligands leads to Egr-l induction [10, 11]. Recently,
v-src has been shown to regulate Egr-l independent of protein
kinase C [12, 13]. Using co-transfection analysis of cloned Egr-l
promoter chloramphenicol acetyl transferase (CAT) constructs
and a temperature-sensitive v-src vector, one can define the
so-called cis elements in the Egr-1 promoter that are targets for
v-src kinase activity. In this manner, it has been shown that the
multiple serum response elements (SREs) present in the Egr-1
promoter serve this function. These elements were first defined
in the c-fos promoter by genetic mutational means and can
confer serum responsiveness to a heterologous gene. More
recently, v-raf, a serine-threonine kinase whose activation
results from the convergence of diverse cell surface signals, has
been found to lead to Egr-l induction. Furthermore, a dominant
negative mutant of v-raf will ablate the v-src induction of Egr- 1,
suggesting that v-src stimulates Egr-l via v-raf (S. Qureshi,
V.P.S., D. Foster, unpublished data). Even if Egr-l served as
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Table 1. 1mmediate-early transcription factor families
Name Transcription factor motif Refs.
Fos (c-fos, fra-1,
fos-B)
Jun (c-fun, jun-B,
jun-D)
Egr (Egr-l, 2, 3, 41
nur 77
Basic DNA binding domain
and leucine zipper
Basic DNA binding domain
and leucine zipper
Cysteine2-histidine2 zinc
fingers
Cys4 zinc finger of steroid
hormone receptor
subtype
3, 23, 24
25, 26, 27,
28, 29
1, 4, 5, 6,
7, 9, 30,
31,32
33, 34
Current status of immediate-early transcription factor (IETF) fami-
lies. Names of independent isolates are as follows: Egr-l = Zif268 =
Krox 24 = Tis 8 NGFI-A; Egr-1 = Krox 20; nur 77 = NGFI-B = N
10 Tis 1.
Table 2. Signals modulating Egr-1 expression
• Induction by multiple second messenger pathways in the context of
a mitogenic stimulus in all mammalian cell types tested to date
• Induction by non-mitogenic stimuli
— neuronal excitation
— hypertrophic responses
— differentiation
— PC12 pheochromocytoma cells
— embryonal carcinoma
— ischemic injury
— X-irradiation
— developmental regulation
— bone/skeletal muscle
Mitogenic as well as many non-mitogenic signals regulate Egr-1
expression in mammalian cells. References are given in [I].
nothing more than just a target marker, these types of studies
are helping to define the circuitry among second messenger
systems.
Since Egr-l induction lies at the convergence of so many
regulators of mitogenesis, it is natural to ask whether Egr- 1 is
itself a proto-oncogene. The situation is highly analogous to that
for c-fos and c-jun since Egr-l, c-fos and c-jun are IETFs, and
the latter two are known oncogenic agents. This question has
turned out to be a difficult one to answer. Early experiments in
fibroblasts utilizing Egr-l expression vectors driven by viral
long terminal repeats (LTRs) so as to provide strong constitu-
live expression did not show a phenotype: namely, morphologic
alterations, changes in growth characteristics, diminished se-
rum requirements, anchorage independence, etc. In some of
these cells, high levels of Egr-l mRNA and protein were noted.
However, the over-expressed Egr-l protein appears to be
non-functional, as measured by its inability to activate a test
reporter plasmid containing multiple Egr- 1 binding sites (se-
quences of the form 5'-GCGGGGGCG-3' known to bind the
Egr-l protein) [9, 14] placed upstream of a minimal promoter
and CAT (I. Drummond, X. Cao and V.P. Sukhatme, unpub-
lished data). Needed is a non-leaky inducible system to circum-
vent this problem and work is ongoing in this direction.
The opposite tack—attempts at abrogating Egr-l activity—
may well prove to be more useful in defining a phenotype. In
this regard, the use of antisense methodology—either as oligo-
nucleotides or in the form of stable inducible vectors—is
currently under investigation. The latter technique when ap-
plied to c-fos has resulted in a remarkable and reversible
inhibition of cell growth [15, 16]. Another approach is also
available to inhibit Egr-1 activity: nature has designed its own
inhibitor of Egr- I activity in the form of a tumor suppressor
gene, one whose absence is likely to be responsible for the
genesis of Wilms' tumor.
To understand the Egr-Wilms' tumor connection, a small
digression is in order. A recent interest in our laboratory is on
kidney development. Essentially, we are trying to identify
genes whose expression is modulated during the conversion of
metanephric mesenchymal cells into epithelium. We have taken
the viewpoint, based on our interest in transcription factors,
that it would be particularly exciting to define a cascade or
hierarchy of these regulatory proteins that occur during this
transition. For this purpose, one can contemplate two ap-
proaches. The first is to utilize known motifs that occur in
transcription factors [8] to screen for the presence of kidney
specific transcription factors; the second is to use a strategy in
which one picks a target kidney specific gene, tries to identify
its promoter and ultimately works backward in developmental
time defining the transcription factors regulating expression of
this kidney specific gene. We are currently attempting both of
these approaches, but here we will focus on the former. We
have isolated several clones from a kidney eDNA library that
contain zinc finger motifs (S. Patwardhan, A. Aplin and V.P.
Sukhatme, unpublished data). Among this set was in fact the
candidate Wilms' tumor gene (WTI) [17, 181, cloned by reverse
genetic means. This gene has an interesting structure: it pre-
dicts a protein with four zinc fingers with a 60 to 70% amino acid
sequence similarity in three out of its four zinc fingers to those
of Egr-1. An antibody, raised by F. Rauscher and his colleagues
against the zinc finger domain of the Wilms' tumor protein
reacts against an 80 kd protein in addition to the 50 kd Wilms'
tumor protein. The 80 kd band corresponds to Egr-1. This result
is very exciting because it suggests that WT1 and Egr-l might
bind to a common DNA sequence. Indeed, this hypothesis
proves to be correct [19]. Next, to determine whether this result
was interesting biochemistry or whether there was some in vivo
correlate, we asked what would happen if both the Wilms'
tumor gene product and Egr-l were present in the same cell.
Such a situation would occur in metanephric mesenchymal cells
since Egr-l expression is modulated in all proliferating cells,
and recent studies have shown that Wilms' tumor expression
coincides with the beginning of condensation of metanephric
mesenchymal cells [20]. In collaboration with the Rauscher
laboratory, we found that the Wilms' tumor protein is able to
repress transcription through an Egr-l binding site. In other
words, transfection of an Egr-l expression plasmid results in
activation from a reporter plasmid containing Egr-l binding
sites, but as increasing amounts of a construct which expresses
WTI are added, there is an abrogation of the activation by
Egr-l. This result is significant because it indicates that Egr-I
and WT1 form a binary on/off system. Furthermore, it was
found that the Wilms' tumor protein also represses transcrip-
tion of the Egr-1 promoter itself (Fig. I).
The last part of this story is an unfinished one. Is there
biological significance to what we have found? We have made a
guess: namely, that there exists a physiologic target for these
two proteins and that this target is the insulin-like growth
factor-Il (IGF-II) gene (Fig. I). Our thinking is as follows: first,
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it has been known that IGF-II levels are high, 10- to 100 fold
elevated in Wilms' tumor samples compared with normal kid-
ney [21, 22]; second, IGF-II is a known mitogen; third, levels of
IGF-II decrease as kidney differentiation proceeds and levels of
WT1 increase during conversion of metanephric mesenchyme
into epithelia [20]; and finally, the IGF-II promoter (which is
quite complex) contains multiple sites for Egr-IIWT1 binding (I.
Drummond and V.P. Sukhatme, unpublished data). Given the
data that WT1 can act as a repressor and Egr-1 as an activator
along with the collective information above and the expected
fact that Egr-1 is upregulated every time a cell receives a
mitogenic signal, we have a potentially exciting model for a key
regulatory event in kidney differentiation (Fig. 1). Essentially
the model is that of an autocrine circuit, a circuit that is broken
during differentiation as WTI levels are upregulated. Therefore,
as differentiation proceeds, WT1 levels rise, IGF-II transcrip-
tion is down regulated and growth comes to a stop. In certain
Wilms' tumor patients, WTI is functionally inactivated and
growth continues. This is surely a simplistic model, but is
possibly a first step. We are currently testing part of this model
using promoter regions of IGF-II to see if in fact WT1 will
repress IGF-II expression. This illustration of the curious
intersection of our studies on Egr- 1 with the Wilms' tumor story
is worth mentioning for two reasons: first, I thought it would be
of interest, especially in this forum on kidney development in
mesangial cells, to show how a ubiquitous factor such as Egr- 1
can in fact interact with a tissue specific factor and give rise to
a rather tissue specific interaction and, second, it may just
happen that it is the kidney that will provide us a phenotype in
which to investigate the effects of overexpression or knocking
out of Egr-1.
Reprint requests to Vikas P. Sukhatme, M.D., Ph.D., University of
Chicago, Pritzker School of Medicine, Department of Medicine, Chi-
cago, Illinois 60637, USA.
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